[Complementary observational study of the efficacy, tolerance and safety of lansoprazole 15 mg as maintenance therapy of reflux esophagitis in daily medical practice in Belgium (record RU49749/R002].
Gastroesophageal reflux disease is a frequent illness with important implications on quality of life. In order to evaluate in a general population the efficacy and safety of lansoprazole 15 mg in maintenance therapy of reflux oesophagitis in current medical practice, an open label observational study was conducted in Belgium. 1.709 patients were included by 429 general practitioners during 3 to 6 months from 1997 to 1999. At the end of the study, symptoms improved or disappeared in 88% of patients. No drug related severe adverse event was reported. This study confirmed that lansoprazole 15 mg is effective and safe in maintenance treatment of reflux oesophagitis.
Penson
J
J
Aventis Pharma, Bruxelles.
Azerad
M A
MA
Puttemans
M
M
Fassotte
C
C
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology*; D011446:Prospective Studies; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D004791:Enzyme Inhibitors; D064747:Lansoprazole; D009853:Omeprazole